KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC50s of 3-10 μM toward both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays. KH7 is also a cAMP inhibitor.
性状
Solid
IC50 & Target[1][2]
IC50: 3-10 μM (recombinant sACt).
体外研究(In Vitro)
KH7 (10 μM) blocks this capacitation-induced cAMP increase. At higher concentrations (50 μM), 5- to 10-fold above its IC50 but still selective for sAC relative to tmACs, KH7 resulted in a significant decrease in the basal cAMP accumulation in sperm regardless of the incubation medium.
KH7 prevents the generation of CaSF.
In the presence of KH7, the myocytes exerts a negative inotropic effect (NIE) of approximately 20%, suggesting that sAC is involved in the normal generation of basal cardiac contractility.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.